Shows what is possible on a news release. ASPX nearly doubled from yesterday's close.
ISIS has far greater potential.
So, you're jealous that the CEO gets compensated for creating billions of dollars of shareholder value?
Just curious - how many multi-billion dollar companies have you run, and gotten FDA to approve your new drugs?
I was waiting for a dip back down below $50 to add to my position, but it just keeps going up.
They will have to defend whatever is filed against them or they will lose in absence.
I'm not sure what you find "Hilarious" - the lawsuits are real and irregardless whether they have a basis or not, the company will have to hire a law firm to defend them, and that costs real money. It is a lose-lose-lose situation no matter how you look at it.
I guess you like to laugh at those???
Sadly, the expected lawsuits are now materializing that will drain financial resources and distract from the core purpose of getting eteplirsen approved. The management team couldn't get the job done without the distractions so I don't know how they have any hope to do it with less money, time, and focus.
I can only think that people are concerned about growth in China and how it will (or will not) affect BITA. I have to think that this is a knee jerk reaction to the macro-level data released this week. While I think it is a valid concern about growth in China, because that can lead to lower spending because advertisers have less money to spend, the opposite could also be true. If there is less buying by Chinese consumers, there will be more competition for those shrinking dollars and therefore advertising becomes incredibly more important. So that could easily offset any decline in BITA revenues.
The bottom line is that while many companies in China may get hit by the economic decline, I think that BITA will survive and thrive going forward. While I'm not ready to buy in yet because the stock is still on the decline, as soon as it bottoms, I'll be looking to take advantage of this discount.
I would offer that the oscillations you see in ISIS are due to fluctuations in the outlook on the drugs and when they will start bearing fruit. ISIS has so many drugs in the pipeline that are so good, it is a compelling buy at under $100 right now. I say this based on the drugs in the pipeline, their probability of being approved multiplied by their projected sales, then discounted based on when that will come to pass. Anything can happen in this market and I'm anticipating a major down-day in the pretty near term that will provide a buying opportunity for those who are ready. I don't think this will be a long term correction, but a short & violent one, then resume upward (market-wide -- nothing specific to ISIS).
ISIS specific - I think it is one of the best stocks to own for the next 5 years and could easily see it go to $500/share in that time frame. Yes there will be volatility, but long term components look extremely favorable.
Looks awful in almost every way. Down 45% year to date. Could get some good news on one of their drugs and spike, but it would be an absolute longshot. There are much better stocks out there that will yield a significantly higher ROI. I wouldn't sell it short but no way I'd buy it.
Interesting Zacks article says EPS estimates were revised upwards from a loss of $0.16 to a profit of $0,04/share.
I didn't see that on the Yahoo analyst estimates, but they could track different analysts, or Zacks could be more current. Yahoo shows a range of a loss of $0.30 to a profit of $0.11.
Are you expecting anything significant at the CES?
When it is dishonest.
An upgrade with no initial position, nor previous downgrade isn't an upgrade at all. Makes me wonder why they would lie about it. Same as a downgrade with no prior rating, or no upgrade, would make me wonder why not just come out with a new rating.
Or, directly to you, why defend a lie?
So looking at Yahoos upgrades, WBB upgraded SRPT to a BUY today but they already did that back on Juky 14 when hey upgraded from a speculative BUY to a BUY.
Strangely, there were no downgrades, how do they upgrade from the same rating?
I'll buy some here and hope to get more at $0.45/share but not sure that it will ever hit that low. This is a reasonable technology play given the approach they are taking.
Compare the chart of ISIS and REGN for the last year. Which one looks better?
ISIS all the way.
The problem with analysis techniques like billing errors bands is that they on,y work in isolation. Meaning, they don't consider things like financial restructuring, released news on clinical trials, anticipated results etc. they only work for stocks like GE etc.